Key concepts in glioblastoma therapy
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Glioblastoma is the most common form of primary brain cancer and remains one of the most aggressive forms of human cancer. Current standard of care involves maximal surgical resection followed by concurrent therapy with radiation and the DNA alkylating agent temozolomide. Despite this aggressive regimen, the median survival remains approximately 14 months. Meaningful strategies for therapeutic intervention are desperately needed. Development of such strategies will require an understanding of the therapeutic concepts that have evolved over the past three decades. This article reviews the key principles that drive the formulation of therapeutic strategies in glioblastoma. Specifically, the concepts of tumour heterogeneity, oncogene addiction, non-oncogene addiction, tumour initiating cells, tumour microenvironment, non-coding sequences and DNA damage response will be reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 1×
“Such a strategy has shown promise in preclinical studies in which breast tumour cells defective to HR appear hypersensitive to inhibition of base excision repair by small molecule inhibitors of poly(ADP-ribose) polymerase (PARP).(96) 108 Of note, PARP inhibition has shown promise in glioblastoma treatment in cell cult…”
BackgroundSelf-citationInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Khalil, A. M., Guttman, M., Huarte, M., Garber, M., Raj, A., Rivea Morales, D., Thomas, K., Presser, A., Bernstein, B. E., van Oudenaarden, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904715106 · Cited by 2,872
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Self-citationIdentification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316 · cited 1×
“Second, among the hallmarks of glioblastomas is their resistance to radiotherapy and chemotherapy.(97) These phenomena highlight the intimate involvement of the cellular DDR network, particularly DNA damage signalling, cell-cycle checkpoints and DNA repair pathways, in the pathobiology of glioblastomas.”
BackgroundA Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response
Huarte, M., Guttman, M., Feldser, D., Garber, M., Koziol, M. J., Kenzelmann-Broz, D., Khalil, A. M., Zuk, O., Amit, I., Rabani, M., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.040 · Cited by 2,053
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garre’, M., Giovanni Nuciforo, P., Bensimon, A., et al. (2006) · Nature · doi:10.1038/nature05327 · Cited by 1,821
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442 · cited 1×
“27 To complicate the matter, recent studies demonstrate that glioblastomas harbour activation of multiple oncogenic receptor tyrosine kinases, such that inactivation of any single oncogene merely diverts signalling through other active oncogenes.”
BackgroundA Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938 · cited 1×
“To complicate the matter, recent studies demonstrate that glioblastomas harbour activation of multiple oncogenic receptor tyrosine kinases, such that inactivation of any single oncogene merely diverts signalling through other active oncogenes.(28) In these contexts, it is evident that meaningful therapy will require s…”
BackgroundAlcantara Llaguno, S., Chen, J., Kwon, C.-H., Jackson, E. L., Li, Y., Burns, D. K., Alvarez-Buylla, A., & Parada, L. F. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.006 · Cited by 694
DNA damage signalling guards against activated oncogenes and tumour progression
Bartek, J., Bartkova, J., & Lukas, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210881 · Cited by 521
Self-citationImmune resistance orchestrated by the tumor microenvironment
Gajewski, T. F., Meng, Y., Blank, C., Brown, I., Kacha, A., Kline, J., & Harlin, H. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00442.x · Cited by 437 · cited 1×
“Indeed, in patients with glioblastoma, tumour progression is seen despite the presence of tumour-infiltrating lymphocytes.(71) Interestingly, glioblastoma’s capacity to suppress immune response appears intimately associated with the process of neoplastic transformation.”
BackgroundTargeting Cancer Stem Cells through L1CAM Suppresses Glioma Growth
Bao, S., Wu, Q., Li, Z., Sathornsumetee, S., Wang, H., McLendon, R. E., Hjelmeland, A. B., & Rich, J. N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1079 · Cited by 427 · cited 1×
“Candidate cell surface molecules suggested in this context include the adhesion glycoprotein L1CAM, 41 surface carbohydrate antigen CD15 (SSEA-1), 42 surface marker A2B5 43 and integrin a 6.”
BackgroundGuo, D., Prins, R. M., Dang, J., Kuga, D., Iwanami, A., Soto, H., Lin, K. Y., Huang, T. T., Akhavan, D., Hock, M. B., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000446 · Cited by 351 · cited 1×
“33 34 Additional examples of such critical non-oncogenic pro-survival functions required for maintenance of the tumorigenic state include dependency on mechanism for compensating mitotic and proteotoxic stress and interplay with the tumour microenvironment including the immune system.”
BackgroundGuo, D., Hildebrandt, I. J., Prins, R. M., Soto, H., Mazzotta, M. M., Dang, J., Czernin, J., Shyy, J. Y.-J., Watson, A. D., Phelps, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906606106 · Cited by 232
Epigenetic mechanisms in glioblastoma multiforme
Nagarajan, R. P., & Costello, J. F. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.02.005 · Cited by 176 · cited 2×
“The term ‘epigenetic regulation’ has been coined to describe the phenomenon that heritable changes in gene expression can occur in the absence of changes in the DNA sequences encoding for gene function.(77) The mechanism underlying this regulation involves cytosine methylation(81) or histone modifications that, in tur…”
Background
Cited by
Yoshimoto, K., Mizoguchi, M., Hata, N., Murata, H., Hatae, R., Amano, T., Nakamizo, A., & Sasaki, T. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00186 · Cited by 126
Xiao, Y., Kim, D., Dura, B., Zhang, K., Yan, R., Li, H., Han, E., Ip, J., Zou, P., Liu, J., et al. (2019) · Advanced Science · doi:10.1002/advs.201801531 · Cited by 115
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
Wang, Z., Li, B., Ren, Y., & Ye, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00353 · Cited by 73
“Genetically modified T cells have been used to target EGFRvIII, only expressed on glioblastoma cells, to establish a basis for future clinical application (141, 143, 144).”
Background
Metadata
- Authors
- Bartek, J., Ng, K., Bartek, J., Fischer, W., Carter, B., & Chen, C. C.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2012-03-06
- Volume
- 83
- Issue
- 7
- Pages
- 753-760
- ISSN
- 0022-3050 (ISSN-L)
- 1468-330X
- OpenAlex
- W2096221839
- Cited by
- 72
- References
- 21
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.